CCS offers the following cardiovascular core laboratory services:

• Study Protocol, CRFs, Site Operating Manual
• Site Training
  • Investigator Meeting
  • Site Conference Call
• Data Transfer Protocol
• Site Communication
• QC Images and Follow Up After Each Study
• Status Updates and Reports to Sponsor

Current Core Lab Trials:

Hemodynamic Tracings

• Acute Decompensated Heart Failure Pivotal – Device, Chronic HF, 200 Patients, 80 Tracings / patient, 40 Sites, Enrolling

SPECT MPI

• Myocardial Stem Cell Phase I - Drug/Device, Chronic HF, 35 Patients, 3 Time Points, 3 Sites, Near Completion
• Myocardial Stem Cell Phase II – 150 Patients, 3 Time Points, 15 Sites, 18-24 Months

Echocardiography

• Familial Amyloid Cardiomyopathy Phase 0 – Natural History, Protein Misfolding, 35 Patients, 5 Time Points, 5-7 Sites, 2 Years
• Pediatric Leukemia Phase I/II – Drug, 40 Patients, 9 Time Points, 7 Sites, 2 Years

MEMS Cap

• Chronic Heart Failure Phase IIIb – Drug, 400 Patients, 1 or 2 Caps/Patient, 50 Sites, Enrollment Complete